Abiopharma

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

General Announcement: RECONSTITUTION OF THE BOARD AND BOARD COMMITTEES

Change - Announcement of Appointment: Appointment of Independent Director

Change - Announcement of Cessation: Announcement of Cessation of Non-Executive Director and Committee Member

Financial Statements and Related Announcement: Half Yearly Results

DCX Announces Open-Market Share Purchase by Chief Executive Officer

Phillips 66 announces additional share repurchase authorization

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: DISCLOSURE IN INTEREST OF DIRECTOR - ZHENG XIANBIN

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thu

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: DISCLOSURE IN INTEREST OF DIRECTOR - DASMOND KOH CHIN ENG